The objectives of the study are to determine the in vitro permeability of different terbinafine hydrochloride formulations through human skin and to measure the respective concentrations of each formulation within the exposed skin tissue. The permeation of three commercially available 1% terbinafine hydrochloride formulations and two terbinafine hydrochloride solutions of 10 and 20 mg/ml through human skin was investigated using an in vitro continuous flow-through perfusion system. The terbinafine hydrochloride retained in the skin was extracted and analysed. The terbinafine hydrochloride from the different formulations readily diffused into the skin tissue. However, no flux values for any of the terbinafine hydrochloride formulations through the skin into the receptor fluid were found. The mean terbinafine hydrochloride concentrations in the skin after 24 h exposure to the three commercial formulations were 3.589, 1.590 and 4.219 ug/ml respectively. The mean terbinafine hydrochloride concentrations in the skin after 24 h of exposure to the terbinafine hydrochloride solutions (PBS/Methanol 1:1) of 10 and 20 mg/ml were 85.280 and 154.680 ug/m] respectively. The mean terbinafine hydrochloride concentration in the skin exposed to the 10 mg/ml PBS/Methanol solution was higher than those from the three commercial formulations. Terbinafine seems to accumulate in skin/bind to the skin, rather than to diffuse through the skin into the receptor compartment. This unique pharmacokinetic property of terbinafine hydrochloride may enhance its efficacy as topical antifungal and reduce systemic side effects.
Dermal and transdermal drug delivery serve as an attractive alternative to conventional drug delivery methods. Topical administration of drugs can be used to achieve systemic or local effects. The barrier properties and the subsequent impermeability of the skin are a considerable problem in the delivery of active compounds both to and through skin. The pharmaceutical industry is therefore investing everincreasing amounts of resources on the development of new products that are able to overcome the barrier properties of the skin (l). Even though the skin is very accessible for drug administration and research, some aspects of transdermal drug penetrations remain unknown.
Due to modem high-throughput technologies large numbers of potential drugs are produced by parallel synthesis and combinatorial chemistry. The pharmaceutical industry therefore requires rapid and accurate methods to screen drug leads for tissue permeability potential in the early stages of drug discovery. In vivo human dermal studies are not always feasible due to the invasiveness of biopsies and the high costs. Even though mathematical models are available for the selection of appropriate transdermal drugs, these models are still ambiguous in predicting skin permeability (2) . Reliable in vitro models can be applied to determine the permeation of test compounds, which will help avoid the wasting of valuable resources for the development of drugs that are destined to fail in preclinical and clinical phases due to insufficient absorption properties. Different types of diffusion equipment are available for the study of in vitro tissue permeability. The different flow cells include the conventional static Franz cells, where an accurate volume of sample must be removed with a simultaneous media replacement, and the Ussing chamber, optimized for the use of high-frequency alternating current stimuli, as well as flow-through diffusion cells (3) (4) . A flow-through diffusion apparatus was used in the present study. One would prefer to use human skin to evaluate the penetration properties of new candidate drugs, since such in vitro studies provide more accurate absorption data than animal skin studies (5) (6) .
Terbinafine hydrochloride is classified as a synthetic allylamine antifungal. It is the most commonly used drug of this new chemical class of antimycotic compounds and has a broad spectrum of antifungal activity at relatively low concentrations. It is marketed for oral and topical use and is highly lipophilic and keratophilic, resulting in high drug concentrations in the stratum corneum, sebum and hair follicles and therefore reducing the probability of reinfection (7) (8) . Since the skin (especially the stratum corneum) is the main target for topical antifungal drug treatment, terbinafine hydrochloride's clinical efficacy can be determined by evaluating the concentration of the drug at its target site. Ideally, a topical antifungal drug should be absorbed by the skin and be able to achieve the desired therapeutic action with minimal systemic exposure. Relatively little information is available in the literature about the concentration of terbinafine hydrochloride in tissues (9) . A possible reason could be due to a lack of availability of an analytical in vitro method (9) .
Choosing the appropriate vehicle/formulation for a specific drug plays a critical role in the clinical efficacy of a topical drug. The formulation has to exhibit qualities such as optimised drug release and at the same time be able to facilitate drug transport across or into the skin.
The foregoing prompted the use of a f1owthrough diffusion system to determine the permeability of different terbinafine hydrochloride formulations through human skin and to measure its concentrations within the skin tissue.
MATERIALS AND METHODS

Human skin
Skin specimens were obtained from excess tissue removed from 11 females, mean age 42 ± 15 SD (range: 20-66) yr, during breast reduction procedures at the Louis Leipoldt Hospital, Bellville, South Africa. No specimens were obtained where there was clinical evidence of any disease that might have influenced the permeability characteristics of the skin (l 0-13).
All skin specimens were immediately placed in a transport fluid after removal and kept at 4°C. The skin tissue was transferred to our laboratory within 2 hours. In the laboratory excess connective tissue was trimmed away. Specimens from each patient (10 x 10 mm) were snap-frozen in liquid nitrogen and stored at -85°C. Full thickness skin was obtained, since the presence of both the epidermis and dermis makes for a more realistic model for in vivo skin and systemic absorption. Previous studies with the in vitro flow-through diffusion system have shown that skin tissue, vaginal and intestinal mucosa can be frozen and banked without their permeability properties to a number of different permeants being changed. In view of the foregoing, the assumption of using frozen/thawed vaginal mucosa, skin tissue and small intestine mucosa for the current permeability study was considered to be a reasonable one (10) (11) . Prior to use the frozen samples were. thawed and hydrated in PBS (phosphate buffered saline) for 24 hours at 4°C (5, (11) (12) .
The study was approved by the Ethics Committee of Stellenbosch University and the Tygerberg Academic Hospital. Project number: 95/019 (resubmitted and approved on 28/7/03).
Terbinafine hydrochloride
Terbinafine hydrochloride powder and three commercially available terbinafine hydrochloride 1% (10 mg/ml) formulations (Topicall, Topical2, and Topica13) were obtained from different pharmaceutical companies. Two terbinafine hydrochloride solutions (PBS/Methanol 1:1) of 10 and 20 mg/ml were prepared. Methanol is known to_cause rapid and irreversible damage to stratum corneum. It interferes with the skin's barrier function by exerting an effect on the stratum corneum's lipids and RESULTS solution was subjected to analysis by LC/MS. No flux values for any of the terbinafine hydrochloride formulations (Topicall, Topica12, Topica13 or terbinafine hydrochloride solutions) through skin into the receptor fluid were found. Terbinafine hydrochloride is a highly lipophilic and keratophilic compound. It readily diffused from its vehicle into the skin, but then accumulated in the skin ("reservoir effect") rather than to diffuse into the hydrophilic receptor compartment through which PBS was pumped. This reservoir effect is in agreement with the findings of other authors (21) (22) (23) .
The mean terbinafine hydrochloride concentrations in the skin after 24 h exposure to Topicall, Topica12 and Topica13 were 3.589, 1.590 and 4.219 ug/ml respectively ( Fig. 1) .
LelMS determination ofterbinafine hydrochloride
The samples collected from the extractions of the exposed skin, were analysed using LC/MS. 
Permeability experiments
The human skin specimens were mounted in f1owthrough diffusion cells (exposed circular areas 0.196 ± 0.002 SD cm-) and permeation studies were performed on 7 tissue replicates for each patient (11-13). Each permeability experiment was repeated six times. The skin was mounted between donor and receptor compartments and the stratum corneum faced towards the donor compartment. 0.5 ml Topicall was placed in the donor compartment of each flow-through diffusion cell and covered with adhesive tape to avoid evaporation.
PBS at 32°C was pumped through the receptor chambers at a rate of 1.5 mllh and collected by means of a fraction collector, at 2-h intervals for 24 h (11-13).
The above experiments were repeated with 0.5 ml (~5 mg terbinafine HC1) Topical2 and Topical3, as well as 0.5 ml terbinafine hydrochloride solutions (PBS/Methanol I: 1) of 10 and 20 mg/ml (10) (11) (12) (13) . The flow-through diffusion cells mimic the blood flow beneath the skin by the continuous flow of PBS though the receptor compartment. The commercial formulations, after their addition to the donor chamber, were capped completely with a tightfitting Teflon disc. The donor compartments containing the terbinafine hydrochloride solutions were closed with plastic adhesive tape to avoid evaporation.
The terbinafine hydrochloride in the receptor chambers was quantified by means of LC/MS (Liquid Chromatography/Mass Spectrometry) analysis and terbinafine hydrochloride extractions of the exposed skin were conducted.
Terbinafine hydrochloride extractions from skin
After each 24 h transdermal diffusion experiment, the skin samples from the diffusion cells were recovered and wiped 3 times using a cotton cloth immersed in PBS to remove excess terbinafine hydrochloride from the surface of the skin. The skin exposed to the different terbinafine hydrochloride formulations were positioned in a glass homogenizer and grounded in 1 ml methanol (5) . The resulting solution was centrifuged for 10 min at 6500 rpm to eliminate suspended solids and impurities from the skin. The terbinafine hydrochloride were then extracted with 10 ml ethyl acetate and the extract was evaporated at 39°C (5). 1 ml methanol was added to the residues and the proteins (14) (15) . The extent of damage increases with the contact time (16) (17) . Topicall and Topical2 were generic cream formulations and contained 1.0% benzyl alcohol as preservative, while Topica13 was a gel formulation and had 0.5% (m/m) benzyl alcohol as well as 10% ethanol (96%, v/v) as preservatives. Ethanol is also commonly used as a solvent and permeation enhancer, but is a much milder solvent than methanol (18) (19) (20) .
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DISCUSSION
The results of this in vitro model are in correlation with Fick's law; the skin absorption rate of a penetrant in a mixture is proportional to the penetrant concentration (24) . As expected, the mean drug concentration of the skin exposed to 20 mg/ml terbinafine hydrochloride solution was almost 2 times (1. 8) higher than the mean drug concentration of the skin exposed to the solution with a lower concentration (10mg/ml). The mean terbinafine hydrochloride skin concentrations after 24 h of exposure to the terbinafine hydrochloride solutions (PBS/Methanol 1:1) of 10 and 20 mg/ml were 85.280 and 154.680 ug/ml respectively (Fig. 2) .
The mean drug concentration of the skin exposed to the 10mg/ml terbinafine hydrochloride solution (PBS/Methanol 1:1) was 11.9 times higher than the mean drug concentration of the skin exposed to Topicall (10mg/ml) and 10.1 times higher than the mean drug concentration of the skin exposed to Topica13 (1Omg/ml) (Fig. 3) .
The results of this in vitro study concur with data from a previous in vitro skin study, in which no flux values for terbinafine through human skin were found (5) . In an in vivo study, the single application of two 1% terbinafine topical products with similar formulations to Topical 1, Topica12 and Topica13 were used and the skin concentrations of the respective formulations were compared by using skin stripping (25) . The topical formulation similar to Topica13 showed a significantly faster skin penetration than the topical formulation similar to Topical 1 and 2. The ratio between the in vivo skin concentrations achieved after 24 h application of the two different formulations was 1.2. Interestingly, the skin concentration ratio achieved in this in vitro study after 24 h application of Topical 1 and 3, was also 1.2.
All three commercial formulations used in this study had a concentration of 10mg/ml. The finding that exposure to Topica13 led to the highest terbinafine hydrochloride penetration in the skin, may be attributed to the combination of benzyl alcohol (0.5%) and ethanol (10%) in the formulation of Topical3, which enhanced the absorption of terbinafine hydrochloride by the skin more Topical3 showed a significantly (p<0.05, ANOYA) higher mean drug concentration (4.219 ug/ml) in the skin than Topica12 (1.590 ug/ml), The mean terbinafine hydrochloride skin concentration after 24 h exposure to Topica13 was higher than the skin exposed to Topicall (3.589 ug/ml), but this difference was not significant.Topical 1 led to a significantly (p<0.05, ANOYA) higher mean terbinafine hydrochloride concentration in skin than Topical2. efficiently than the 1.0% benzyl alcohol formulation of the other two generic formulations. These results correlate well with an in vivo study carried out by Cramer et al. (26) , where the authors compared the skin penetration of similar commercial terbinafine hydrochloride formulations.
Topicall and Topical2 were generic formulations that contained 1.0% benzyl alcohol as preservative. The 24-hour skin exposure to these two formulations led to a significantly higher mean terbinafine hydrochloride concentration in the skin exposed to Topical 1, even though the two formulations are from a similar pharmaceutical category (generics). This interesting result may be attributed to the fact that they are manufactured by different pharmaceutical companies. The findings of the present study are therefore in agreement with Hadgraft et al. (27) , who concluded that generic prescriptions and formulations cannot always be assumed to be pharmaceutically and clinically equivalent and interchangeable.
The mean drug concentration of the skin exposed to l Omg/ml terbinafine hydrochloride solution (PBS/ Methanol 1:1) was 10.1 times higher than the mean drug concentration of the skin exposed to Topica13 (10 mg/ml, 1% benzyl alcohol, 10% ethanol) ( Fig.  3 ). This result confirms the more destructive effects of methanol on skin integrity compared to methanol. Despite methanol's damage to the stratum corneum, terbinafine did not diffuse through the skin to the receptor compartment.
In conclusion, the results of the present study show that terbinafine hydrochloride from different formulations diffused readily into skin tissue, but no flux values through skin into the receptor fluid were observed with any of the formulations. This reservoir effect of terbinafine hydrochloride has clinical value, since the accumulation of terbinafine hydrochloride in the skin tissue reduce systemic absorption. The model used in this study has demonstrated that the uptake of terbinafine hydrochloride by the skin can be determined by this in vitro model.
